Gilead Sciences: Breast Neoplasms trials

The registry lists 10 Breast Neoplasms studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 3Phase 2 4Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerCompletedNCT03901339Phase 3Results posted
• GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerTerminatedNCT02983604Phase 1/2Results posted
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT02574455Phase 3Results posted
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted
• A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in SpainCompletedNCT06683482
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyActive, not recruitingNCT05840211Phase 3
• Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Active, not recruitingNCT04639986Phase 3
• Expanded Access for IMMU-132Approved for marketingNCT04320693
• Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerWithdrawnNCT02161679Phase 2
• Safety Study of hMN14 to Treat Either Colorectal or Breast CancerCompletedNCT00041652Phase 1/2